Cargando…
Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report
BACKGROUND: Immune checkpoint inhibitors, including programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) have recently been approved to treat locally advanced and metastatic urothelial carcinoma (UC). However, some patients experience rapid tumor progression rather than any clinical benef...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600846/ https://www.ncbi.nlm.nih.gov/pubmed/37901032 http://dx.doi.org/10.12998/wjcc.v11.i28.6841 |